Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2021-05-10
• Target enrollment: 0
• Participant gender: All

Summary

Patients with diabetes are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. In previous observational study, the investigators found that liraglutide can improve cognitive function in patients with T2DM through a metabolism-independent pathway. Here the investigators aim to further verify such effects through a randomized, controlled study.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Military Medical University
• Treatments: 2,4-thiazolidinedione; Hypoglycemic Agents; Liraglutide; Metformin

Criteria

Inclusion Criteria:

• Patients with Type 2 Diabetes Mellitus

Exclusion Criteria:

• T2DM with acute diabetic complications;

• type 1 diabetes;

• other diseases affecting cognitive function (e.g., congenital dementia, brain trauma, epilepsy, severe hypoglycemic coma, cerebrovascular disease, ischemic heart disease, renal dysfunction);

• alcohol abuse, mental illness, and psychoactive substance abuse;

• history of thyroid disease;

• any surgical or medical conditions that could significantly influence the absorption, distribution, metabolism, or excretion of interventional drugs;

• unwillingness to provide informed consent.